José Cláudio Fonseca Moreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
José Cláudio Fonseca Moreira has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Pens Gelain
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
10 shared publications - Carolina Saibro Girardi
Universidade Federal do Rio Grande do Sul, Brazil
7 shared publications - Lucas Santos
Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
6 shared publications - Juciano Gasparotto
Centro de Estudos em Estresse Oxidativo, Departamento de Bioquimica, Instituto de Ciencias Basicas da Saude, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
4 shared publications - Reykla Ramon Bittencourt
Centro de Estudos em Estresse Oxidativo, Departamento de Bioquímica Instituto de Ciências Básicas da Saúde—Universidade Federal do Rio Grande do Sul (ICBS‐UFRGS) Porto Alegre RS Brazil
4 shared publications - Felipe Dal-Pizzol
Laboratory of Experimental Pathophysiology, Graduate Program in Health Sciences, University of Southern Santa Catarina, Criciúma, SC, Brazil
3 shared publications
Latest Publications
- Open Access
- 10 May 2026
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 31 (4) , 100180
Extracellular 70 kDa heat shock protein in blood plasma binds insulin and modulates glycaemic control in vivo
- 10 May 2026
- Published by Elsevier in Cell Stress and Chaperones
- Vol. 31 (4) , 100180
Open AccessExtracellular 70 kDa heat shock protein in blood plasma binds insulin and modulates glycaemic control in vivo
- Open Access
- 2 February 2026
- Published by Elsevier in Neuroscience
- Vol. 599, 76-93
Limitations and opportunities in multi-omics integration for neurodevelopmental, neurodegenerative and psychiatric disorders: A systematic review
- 2 February 2026
- Published by Elsevier in Neuroscience
- Vol. 599, 76-93
Open AccessLimitations and opportunities in multi-omics integration for neurodevelopmental, neurodegenerative and psychiatric disorders: A systematic review
- Open Access
- 24 January 2026
- Published by Springer Nature in Neurochemical Research
- Vol. 51 (1) , 60
Metformin Ameliorates Cognitive Deficits and Neuroinflammation in a Mouse Model of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.
- 24 January 2026
- Published by Springer Nature in Neurochemical Research
- Vol. 51 (1) , 60
Open AccessMetformin Ameliorates Cognitive Deficits and Neuroinflammation in a Mouse Model of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Animal Reproduction
- Vol. 23 (2)
Tricaine methanesulfonate and eugenol during semen collection do not affect fertilization and hatching rates on Rhamdia quelen
The reproduction of some fish species in captivity is only possible by imposing artificial reproductive procedures, and the manipulation of fish for these purposes is a stressor. Thus, anesthesia can reduce stress during handling. However, it is necessary to investigate the possible side effects on breeding and the general health of the animal. Therefore, we aimed to investigate the impact of tricaine methanesulfonate (MS-222) and eugenol (EUG) at concentrations of 300 mg L-1 and 40 mg L-1, respectively, on several stress- and reproductive-related parameters in Rhamdia quelen anesthetized before semen collection. After hormonal induction, 24 sexually mature males (534.4 ± 259 g) were randomly assigned to treatment groups and semen and blood samples were collected. Anesthesia recovery and induction time were extended in fish anesthetized with EUG; however, plasma cortisol concentrations did not differ among the treatment groups. EUG caused higher DNA fragmentation in blood cells than in the control group (without anesthesia). EUG increased the monocyte count compared to the other experimental groups. MS-222 showed a lower sulfhydryl group (SH) quantitation than the other experimental groups. The anesthetics used before semen collection in this study had no adverse effects on the fertilization or hatching capacity of anesthetized R. quelen. MS-222 (300 mg L-1) and EUG (40 mg L-1), despite being related to hematological and semen changes, did not negatively affect the reproductive capacity of R. quelen males. Thus, anesthesia is recommended for R. quelen during semen collection, considering reproductive parameters and animal welfare.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Animal Reproduction
- Vol. 23 (2)
Open AccessTricaine methanesulfonate and eugenol during semen collection do not affect fertilization and hatching rates on Rhamdia quelen
The reproduction of some fish species in captivity is only possible by imposing artificial reproductive procedures, and the manipulation of fish for these purposes is a stressor. Thus, anesthesia can reduce stress during handling. However, it is necessary to investigate the possible side effects on breeding and the general health of the animal. Therefore, we aimed to investigate the impact of tricaine methanesulfonate (MS-222) and eugenol (EUG) at concentrations of 300 mg L-1 and 40 mg L-1, respectively, on several stress- and reproductive-related parameters in Rhamdia quelen anesthetized before semen collection. After hormonal induction, 24 sexually mature males (534.4 ± 259 g) were randomly assigned to treatment groups and semen and blood samples were collected. Anesthesia recovery and induction time were extended in fish anesthetized with EUG; however, plasma cortisol concentrations did not differ among the treatment groups. EUG caused higher DNA fragmentation in blood cells than in the control group (without anesthesia). EUG increased the monocyte count compared to the other experimental groups. MS-222 showed a lower sulfhydryl group (SH) quantitation than the other experimental groups. The anesthetics used before semen collection in this study had no adverse effects on the fertilization or hatching capacity of anesthetized R. quelen. MS-222 (300 mg L-1) and EUG (40 mg L-1), despite being related to hematological and semen changes, did not negatively affect the reproductive capacity of R. quelen males. Thus, anesthesia is recommended for R. quelen during semen collection, considering reproductive parameters and animal welfare.
- Open Access
- 1 January 2024
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 36
Identification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients
Objective To investigate the relationship between the levels of adipokines and other endocrine biomarkers and patient outcomes in hospitalized patients with COVID-19. Methods In a prospective study that included 213 subjects with COVID-19 admitted to the intensive care unit, we measured the levels of cortisol, C-peptide, glucagon-like peptide-1, insulin, peptide YY, ghrelin, leptin, and resistin.; their contributions to patient clustering, disease severity, and predicting in-hospital mortality were analyzed. Results Cortisol, resistin, leptin, insulin, and ghrelin levels significantly differed between severity groups, as defined by the World Health Organization severity scale. Additionally, lower ghrelin and higher cortisol levels were associated with mortality. Adding biomarkers to the clinical predictors of mortality significantly improved accuracy in determining prognosis. Phenotyping of subjects based on plasma biomarker levels yielded two different phenotypes that were associated with disease severity, but not mortality. Conclusion As a single biomarker, only cortisol was independently associated with mortality; however, metabolic biomarkers could improve mortality prediction when added to clinical parameters. Metabolic biomarker phenotypes were differentially distributed according to COVID-19 severity but were not associated with mortality.
- 1 January 2024
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 36
Open AccessIdentification of distinct phenotypes and improving prognosis using metabolic biomarkers in COVID-19 patients
Objective To investigate the relationship between the levels of adipokines and other endocrine biomarkers and patient outcomes in hospitalized patients with COVID-19. Methods In a prospective study that included 213 subjects with COVID-19 admitted to the intensive care unit, we measured the levels of cortisol, C-peptide, glucagon-like peptide-1, insulin, peptide YY, ghrelin, leptin, and resistin.; their contributions to patient clustering, disease severity, and predicting in-hospital mortality were analyzed. Results Cortisol, resistin, leptin, insulin, and ghrelin levels significantly differed between severity groups, as defined by the World Health Organization severity scale. Additionally, lower ghrelin and higher cortisol levels were associated with mortality. Adding biomarkers to the clinical predictors of mortality significantly improved accuracy in determining prognosis. Phenotyping of subjects based on plasma biomarker levels yielded two different phenotypes that were associated with disease severity, but not mortality. Conclusion As a single biomarker, only cortisol was independently associated with mortality; however, metabolic biomarkers could improve mortality prediction when added to clinical parameters. Metabolic biomarker phenotypes were differentially distributed according to COVID-19 severity but were not associated with mortality.
- Open Access
- 1 January 2024
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 36
Identificação de fenótipos distintos e melhoria do prognóstico usando biomarcadores metabólicos em pacientes com COVID-19
RESUMO Objetivo Investigar a relação entre os níveis de adipocinas e outros biomarcadores endócrinos e os desfechos em pacientes hospitalizados com COVID-19. Métodos Estudo prospectivo que incluiu 213 indivíduos com COVID-19 internados na unidade de terapia intensiva, em que foram medidos os níveis de cortisol, peptídeo-C, peptídeo-1 semelhante ao glucagon, insulina, peptídeo YY, grelina, leptina e resistina; analisamos suas contribuições para o agrupamento de pacientes, gravidade da doença e previsão de mortalidade hospitalar. Resultados Os níveis de cortisol, resistina, leptina, insulina e grelina diferiram significativamente entre os grupos por gravidade, conforme definido pela escala de gravidade da Organização Mundial da Saúde. Além disso, níveis mais baixos de grelina e mais altos de cortisol foram associados à mortalidade. A adição de biomarcadores aos preditores clínicos de mortalidade melhorou significativamente a precisão na determinação do prognóstico. A fenotipagem de indivíduos com base nos níveis de biomarcadores plasmáticos produziu dois fenótipos diferentes, que foram associados à gravidade da doença, mas não à mortalidade. Conclusão Como único biomarcador, apenas o cortisol foi independentemente associado à mortalidade; no entanto, os biomarcadores metabólicos podem melhorar a previsão de mortalidade quando associados a parâmetros clínicos. Os fenótipos dos biomarcadores metabólicos foram distribuídos diferencialmente, conforme a gravidade da COVID-19, mas não foram associados à mortalidade.
- 1 January 2024
- Published by Associação de Medicina Intensiva Brasileira in Critical Care Science
- Vol. 36
Open AccessIdentificação de fenótipos distintos e melhoria do prognóstico usando biomarcadores metabólicos em pacientes com COVID-19
RESUMO Objetivo Investigar a relação entre os níveis de adipocinas e outros biomarcadores endócrinos e os desfechos em pacientes hospitalizados com COVID-19. Métodos Estudo prospectivo que incluiu 213 indivíduos com COVID-19 internados na unidade de terapia intensiva, em que foram medidos os níveis de cortisol, peptídeo-C, peptídeo-1 semelhante ao glucagon, insulina, peptídeo YY, grelina, leptina e resistina; analisamos suas contribuições para o agrupamento de pacientes, gravidade da doença e previsão de mortalidade hospitalar. Resultados Os níveis de cortisol, resistina, leptina, insulina e grelina diferiram significativamente entre os grupos por gravidade, conforme definido pela escala de gravidade da Organização Mundial da Saúde. Além disso, níveis mais baixos de grelina e mais altos de cortisol foram associados à mortalidade. A adição de biomarcadores aos preditores clínicos de mortalidade melhorou significativamente a precisão na determinação do prognóstico. A fenotipagem de indivíduos com base nos níveis de biomarcadores plasmáticos produziu dois fenótipos diferentes, que foram associados à gravidade da doença, mas não à mortalidade. Conclusão Como único biomarcador, apenas o cortisol foi independentemente associado à mortalidade; no entanto, os biomarcadores metabólicos podem melhorar a previsão de mortalidade quando associados a parâmetros clínicos. Os fenótipos dos biomarcadores metabólicos foram distribuídos diferencialmente, conforme a gravidade da COVID-19, mas não foram associados à mortalidade.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 57, e13286
Guarana (Paullinia cupana) as a potential tool for mesenchymal stromal cells priming in regenerative medicine
Mesenchymal stromal cells (MSCs) have therapeutic potential due to their abilities of differentiation, immunomodulation, and migration to injured tissues, potentiating such effects when cells are activated. Guarana (Paullinia cupana) is a tropical plant species found in South America that is known for its antioxidant, stimulant, and cicatricial effects. The guarana extract is composed of many substances and caffeine is the main component. The objective was to evaluate the effects of guarana and caffeine on MSCs. After the initial characterization, MSCs were treated with Paullinia cupana (10, 100, and 1000 μg/mL) or caffeine (0.4, 4, and 40 μg/mL) for 24 h. MSCs treatment with 1000 μg/mL guarana increased cell polarity, viability, cell migration to chemoattractant, antioxidant potential, and liberation of extracellular vesicles (EVs), while it reduced the levels of autophagy. MSCs treated with 100 and 1000 μg/mL guarana or 40 μg/mL caffeine showed a decrease of cell proliferation. No treatment affected the cellular area and cell cycle of MSCs. The study shows in vitro evidence that guarana could be a promising alternative for activating MSCs to promote better cellular products for future clinical therapies.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 57, e13286
Open AccessGuarana (Paullinia cupana) as a potential tool for mesenchymal stromal cells priming in regenerative medicine
Mesenchymal stromal cells (MSCs) have therapeutic potential due to their abilities of differentiation, immunomodulation, and migration to injured tissues, potentiating such effects when cells are activated. Guarana (Paullinia cupana) is a tropical plant species found in South America that is known for its antioxidant, stimulant, and cicatricial effects. The guarana extract is composed of many substances and caffeine is the main component. The objective was to evaluate the effects of guarana and caffeine on MSCs. After the initial characterization, MSCs were treated with Paullinia cupana (10, 100, and 1000 μg/mL) or caffeine (0.4, 4, and 40 μg/mL) for 24 h. MSCs treatment with 1000 μg/mL guarana increased cell polarity, viability, cell migration to chemoattractant, antioxidant potential, and liberation of extracellular vesicles (EVs), while it reduced the levels of autophagy. MSCs treated with 100 and 1000 μg/mL guarana or 40 μg/mL caffeine showed a decrease of cell proliferation. No treatment affected the cellular area and cell cycle of MSCs. The study shows in vitro evidence that guarana could be a promising alternative for activating MSCs to promote better cellular products for future clinical therapies.
- 20 November 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1527-1545
Bexarotene drives the self‐renewing proliferation of adult neural stem cells, promotes neuron‐glial fate shift, and regulates late neuronal differentiation
Treatment with bexarotene, a selective retinoid X receptor (RXR) agonist, significantly improves behavioral dysfunctions in various neurodegenerative animal models. Additionally, it activates neurodevelopmental and plasticity pathways in the brains of adult mice. Our objective was to investigate the impact of RXR activation by bexarotene on adult neural stem cells (aNSC) and their cell lineages. To achieve this, we treated NSCs isolated from the subventricular zone (SVZ) of adult rat brains from the proliferative stage to the differentiated status. The results showed that bexarotene‐treated aNSC exhibited increased BrdU incorporation, SOX2+ dividing cell pairs, and cell migration from neurospheres, revealing that the treatment promotes self‐renewing proliferation and cell motility in SVZ‐aNCS. Furthermore, bexarotene induced a cell fate shift characterized by a significant increase in GFAP+/S100B+ differentiated astrocytes, which uncovers the participation of activated‐RXR in astrogenesis. In the neuronal lineage, the fate shift was counteracted by bexarotene‐induced enhancement of NeuN+ nuclei together with neurite network outgrowth, indicating that the RXR agonist stimulates SVZ‐aNCS neuronal differentiation at later stages. These findings establish new connections between RXR activation, astro‐ and neurogenesis in the adult brain, and contribute to the development of therapeutic strategies targeting nuclear receptors for neural repair. image
- 20 November 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1527-1545
Bexarotene drives the self‐renewing proliferation of adult neural stem cells, promotes neuron‐glial fate shift, and regulates late neuronal differentiation
Treatment with bexarotene, a selective retinoid X receptor (RXR) agonist, significantly improves behavioral dysfunctions in various neurodegenerative animal models. Additionally, it activates neurodevelopmental and plasticity pathways in the brains of adult mice. Our objective was to investigate the impact of RXR activation by bexarotene on adult neural stem cells (aNSC) and their cell lineages. To achieve this, we treated NSCs isolated from the subventricular zone (SVZ) of adult rat brains from the proliferative stage to the differentiated status. The results showed that bexarotene‐treated aNSC exhibited increased BrdU incorporation, SOX2+ dividing cell pairs, and cell migration from neurospheres, revealing that the treatment promotes self‐renewing proliferation and cell motility in SVZ‐aNCS. Furthermore, bexarotene induced a cell fate shift characterized by a significant increase in GFAP+/S100B+ differentiated astrocytes, which uncovers the participation of activated‐RXR in astrogenesis. In the neuronal lineage, the fate shift was counteracted by bexarotene‐induced enhancement of NeuN+ nuclei together with neurite network outgrowth, indicating that the RXR agonist stimulates SVZ‐aNCS neuronal differentiation at later stages. These findings establish new connections between RXR activation, astro‐ and neurogenesis in the adult brain, and contribute to the development of therapeutic strategies targeting nuclear receptors for neural repair. image
- 3 September 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1587-1607
Increased alpha‐synuclein and neuroinflammation in the substantia nigra triggered by systemic inflammation are reversed by targeted inhibition of the receptor for advanced glycation end products (RAGE)
The receptor for advanced glycation end products (RAGE) is a protein of the immunoglobulin superfamily capable of regulating inflammation. Considering the role of this receptor in the initiation and establishment of neuroinflammation, and the limited understanding of the function of RAGE in the maintenance of this condition, this study describes the effects of RAGE inhibition in the brain, through an intranasal treatment with the antagonist FPS‐ZM1, in an animal model of chronic neuroinflammation induced by acute intraperitoneal injection of lipopolysaccharide (LPS). Seventy days after LPS administration (2 mg/kg, i.p.), Wistar rats received, intranasally, 1.2 mg of FPS‐ZM1 over 14 days. On days 88 and 89, the animals were submitted to the open‐field test and were killed on day 90 after the intraperitoneal injection of LPS. Our results indicate that blockade of encephalic RAGE attenuates LPS‐induced chronic neuroinflammation in different brain regions. Furthermore, we found that intranasal FPS‐ZM1 administration reduced levels of gliosis markers, RAGE ligands, and α‐synuclein in the substantia nigra pars compacta. Additionally, the treatment also reversed the increase in S100 calcium‐binding protein B (RAGE ligand) in the cerebrospinal fluid and the cognitive‐behavioral deficits promoted by LPS—less time spent in the central zone of the open‐field arena (more time in the lateral zones), decreased total distance traveled, and increased number of freezing episodes. In summary, our study demonstrates the prominent role of RAGE in the maintenance of a chronic neuroinflammatory state triggered by a single episode of systemic inflammation and also points to possible future RAGE‐based therapeutic approaches to treat conditions in which chronic neuroinflammation and increased α‐synuclein levels could play a relevant role, such as in Parkinson's disease. image
- 3 September 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1587-1607
Increased alpha‐synuclein and neuroinflammation in the substantia nigra triggered by systemic inflammation are reversed by targeted inhibition of the receptor for advanced glycation end products (RAGE)
The receptor for advanced glycation end products (RAGE) is a protein of the immunoglobulin superfamily capable of regulating inflammation. Considering the role of this receptor in the initiation and establishment of neuroinflammation, and the limited understanding of the function of RAGE in the maintenance of this condition, this study describes the effects of RAGE inhibition in the brain, through an intranasal treatment with the antagonist FPS‐ZM1, in an animal model of chronic neuroinflammation induced by acute intraperitoneal injection of lipopolysaccharide (LPS). Seventy days after LPS administration (2 mg/kg, i.p.), Wistar rats received, intranasally, 1.2 mg of FPS‐ZM1 over 14 days. On days 88 and 89, the animals were submitted to the open‐field test and were killed on day 90 after the intraperitoneal injection of LPS. Our results indicate that blockade of encephalic RAGE attenuates LPS‐induced chronic neuroinflammation in different brain regions. Furthermore, we found that intranasal FPS‐ZM1 administration reduced levels of gliosis markers, RAGE ligands, and α‐synuclein in the substantia nigra pars compacta. Additionally, the treatment also reversed the increase in S100 calcium‐binding protein B (RAGE ligand) in the cerebrospinal fluid and the cognitive‐behavioral deficits promoted by LPS—less time spent in the central zone of the open‐field arena (more time in the lateral zones), decreased total distance traveled, and increased number of freezing episodes. In summary, our study demonstrates the prominent role of RAGE in the maintenance of a chronic neuroinflammatory state triggered by a single episode of systemic inflammation and also points to possible future RAGE‐based therapeutic approaches to treat conditions in which chronic neuroinflammation and increased α‐synuclein levels could play a relevant role, such as in Parkinson's disease. image
- 28 June 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1608-1624
Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson's disease
The receptor for advanced glycation end products (RAGE) is a transmembrane receptor that belongs to the immunoglobulin superfamily and is extensively associated with chronic inflammation in non‐transmissible diseases. As chronic inflammation is consistently present in neurodegenerative diseases, it was largely assumed that RAGE could act as a critical modulator of neuroinflammation in Parkinson's disease (PD), similar to what was reported for Alzheimer's disease (AD), where RAGE is postulated to mediate pro‐inflammatory signaling in microglia by binding to amyloid‐β peptide. However, accumulating evidence from studies of RAGE in PD models suggests a less obvious scenario. Here, we review physiological aspects of RAGE and address the current questions about the potential involvement of this receptor in the cellular events that may be critical for the development and progression of PD, exploring possible mechanisms beyond the classical view of the microglial activation/neuroinflammation/neurodegeneration axis that is widely assumed to be the general mechanism of RAGE action in the adult brain. image
- 28 June 2023
- Published by Wiley in Journal of Neurochemistry
- Vol. 168 (8) , 1608-1624
Is it all the RAGE? Defining the role of the receptor for advanced glycation end products in Parkinson's disease
The receptor for advanced glycation end products (RAGE) is a transmembrane receptor that belongs to the immunoglobulin superfamily and is extensively associated with chronic inflammation in non‐transmissible diseases. As chronic inflammation is consistently present in neurodegenerative diseases, it was largely assumed that RAGE could act as a critical modulator of neuroinflammation in Parkinson's disease (PD), similar to what was reported for Alzheimer's disease (AD), where RAGE is postulated to mediate pro‐inflammatory signaling in microglia by binding to amyloid‐β peptide. However, accumulating evidence from studies of RAGE in PD models suggests a less obvious scenario. Here, we review physiological aspects of RAGE and address the current questions about the potential involvement of this receptor in the cellular events that may be critical for the development and progression of PD, exploring possible mechanisms beyond the classical view of the microglial activation/neuroinflammation/neurodegeneration axis that is widely assumed to be the general mechanism of RAGE action in the adult brain. image